(OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis, stroke, dementia, and Alzheimer's disease, announced its ...

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 ...

Pfizer’s “golden egg” has hatched. The subcutaneous PD-1 inhibitor improved outcomes when added to the standard of care in ...

On 18 December 2024, the World Health Organization (WHO) prequalified the first diagnostic test for glucose-6-phosphate ...

An international team of UK and US scientists has discovered that the activity of macrophages—a type of white blood cell that ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Learn about Arbutus's promising Hepatitis B treatments, strong financial position, and projections for the global market.

Doctors around the world may soon have access to a new tool that could better predict whether individual cancer patients will ...

Doctors around the world may soon have access to a new tool that could better predict whether individual cancer patients will benefit from immune checkpoint inhibitors - a type of immunotherapy - ...